by Eric Christianson | Jun 8, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
Angiotensin II receptor blockers (ARBs) are widely used in managing hypertension, heart failure, chronic kidney disease (CKD), and diabetic nephropathy. While these agents share a common mechanism—blocking the angiotensin II type 1 (AT₁) receptor—not all ARBs are...
by Eric Christianson | Sep 27, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
Angiotensin Receptor Blockers are one of the most commonly used drug classes to manage hypertension. Many clinicians prefer using these medications even over ACE inhibitors to reduce the risk of running into the ACE inhibitor-related cough. This is the primary...
by Eric Christianson | Aug 13, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
If you work with patients at all, you’ll see some of the most common antihypertensive agents used on a daily basis. The reason they are used so frequently is because they do not tend to have many significant drug interactions. However, some do exist and I wanted...
by Eric Christianson | Feb 12, 2023 | Clinical Guideline Updates For Pharmacists
Heart failure is a disease state that requires a significant number of medications. Guideline-based standards of care now include numerous medications. How did we get there? I outline my top 5 heart failure clinical trials of all time. Feel free to leave a comment if...
by Eric Christianson | Mar 28, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Sacubitril/valsartan (ARNI) is getting more attention in the guidelines with regards to its use in heart failure (specifically HFrEF). Many patients are already on an ACE and making the transition from an ACE inhibitor to an ARNI is likely something you will come...
